Busted! DEA Shuts Down Risky Texas Pharmacy for Good
Published Date: 10/7/2026
Notice
Summary
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Revokes Arenbii Pharmacy Registration
The Drug Enforcement Administration revoked Arenbii Pharmacy LLC's DEA Certificate of Registration No. FA3529849. The revocation is effective November 6, 2026, following findings about the pharmacy's dispensing conduct covering at least January 10, 2024 through May 12, 2025.
Pending Renewal and New Applications Denied
The Order also denies any pending application by Arenbii Pharmacy LLC to renew or modify its registration and denies any other pending application for additional registration in Texas. That denial is part of the same Order effective November 6, 2026.
DEA Documents Red-Flag Dispensing Patterns
DEA found Arenbii repeatedly dispensed controlled substances with multiple red flags of abuse or diversion, including at least 67 oxycodone prescriptions over a three-year period, at least 30 promethazine-with-codeine prescriptions between October 22, 2024 and April 30, 2025, and at least 16 hydrocodone/acetaminophen prescriptions between May 2 and December 26, 2024. Those factual findings were relied on to determine the pharmacy's registration was inconsistent with the public interest.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
2026-20552, Wellwise Pharmacy Inc.; Decision and Order
Wellwise Pharmacy in Texas had its DEA registration suspended and is facing revocation because it kept filling risky prescriptions for controlled drugs without checking warning signs. This affects the pharmacy’s ability to legally handle these medicines, protecting public health and safety. The decision took effect immediately in late 2025, stopping Wellwise from operating under its DEA license and signaling serious legal and financial trouble ahead.
Previous / Next Documents
Previous: 2026-20534, Agency Information Collection Activities; Proposed eCollection eComments Requested; Title-Identity History Summary Request Form (1-783)
The FBI’s Criminal Justice Information Services wants to update the Identity History Summary Request Form (1-783) and is asking for your feedback by November 5, 2026. This affects anyone who requests their criminal history info and aims to make the process easier and faster, possibly with more electronic options. No big cost changes are expected, but your input helps keep things smooth and user-friendly!
Next: 2026-20536, Privacy Act of 1974; Systems of Records
The Department of Justice is launching a new electronic system to handle applications for restoring federal firearms rights. This system will help track and decide on these requests faster and more securely, starting right after November 6, 2026. If you’re applying to get your firearms rights back, this change affects you and aims to make the process smoother without extra costs.